| Literature DB >> 33595131 |
Camiel de Roij van Zuijdewijn1,2, Wim van Dorp1, Sandrine Florquin3, Joris Roelofs3, Kees Verburgh1.
Abstract
From rat studies, human case reports and cohort studies, bisphosphonates seem to impair renal function. However, when critically reviewing the literature, zoledronate and pamidronate are more frequently involved in renal deterioration than other bisphosphonates. When bisphosphonate nephropathy occurs, zoledronate more frequently induces tubular toxicity whereas pamidronate typically induces focal segmental glomerulosclerosis (FSGS). Thus, although bisphosphonates are highly effective in preventing complications for patients with osseous metastases and are highly effective in preventing fractures for patients with osteoporosis, renal function should be monitored closely after initiation of these drugs. This article is protected by copyright. All rights reserved.Entities:
Keywords: FSGS; bisphosphonate; mevalonate pathway; nephropathy; pamidronate; tubular toxicity; zoledronate
Year: 2021 PMID: 33595131 DOI: 10.1111/bcp.14780
Source DB: PubMed Journal: Br J Clin Pharmacol ISSN: 0306-5251 Impact factor: 4.335